Operating costs - Disclosure of Gross Profit and Operating Cost Explanatory (Details) - EUR (€) € in Millions |
12 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 06, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | ||||||||||||
| Turnover | € 50,503 | € 52,479 | [1] | € 51,680 | [1] | |||||||
| Cost of sales | (26,794) | (27,976) | (29,180) | |||||||||
| Distribution costs | (2,704) | (2,649) | (2,716) | |||||||||
| Production costs | (2,972) | (3,064) | (2,972) | |||||||||
| Raw and packaging materials and goods purchased for resale | (19,643) | (20,781) | (21,996) | |||||||||
| Other | (1,476) | (1,482) | (1,495) | |||||||||
| Gross profit | 23,709 | 24,503 | 22,500 | |||||||||
| Selling and administrative expenses | (13,624) | (14,305) | (13,421) | |||||||||
| Brand and marketing investment | (8,142) | (8,378) | (7,563) | |||||||||
| Overheads | (5,482) | (5,928) | (5,858) | |||||||||
| Research and development | (836) | (892) | (853) | |||||||||
| (Loss)/gain on disposal of group companies | [2] | (36) | (229) | [1] | 491 | [1] | ||||||
| Acquisition and disposal-related costs | (288) | (293) | (222) | |||||||||
| Restructuring costs | (599) | (710) | (425) | |||||||||
| Impairments | (43) | (134) | 0 | |||||||||
| Other | (81) | (3) | 75 | |||||||||
| Operating profit | 9,037 | 8,829 | [1],[3] | 8,998 | [1],[3] | |||||||
| Patent costs | 24 | 26 | 27 | |||||||||
| Gain on disposal | € 4,409 | |||||||||||
| Suave | ||||||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | ||||||||||||
| Gain on disposal | 497 | |||||||||||
| Nutrafol and OZiva | ||||||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | ||||||||||||
| Loss on revaluation of minority interest liability | 98 | 225 | € 104 | |||||||||
| Ice Cream Business | ||||||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | ||||||||||||
| Loss on revaluation of minority interest liability | 91 | |||||||||||
| REN | ||||||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | ||||||||||||
| Impairments | € (42) | |||||||||||
| Blueair | ||||||||||||
| Disclosure of attribution of expenses by nature to their function [line items] | ||||||||||||
| Impairments | € (127) | |||||||||||
| ||||||||||||